On August 7 2023, THERAVANCE BIOPHARMA ($NASDAQ:TBPH) reported their financial results for the second quarter of FY 2023, ending June 30 2023. The company saw a 24.4% revenue increase to USD 13.8 million, compared to the same period in the previous year. However, net income decreased by 8.2 million to USD -15.6 million.
The company stated that these investments are in line with their commitment to bring innovative treatments to market for patients worldwide. Overall, THERAVANCE BIOPHARMA’s second quarter results show a strong performance from the company, and a promising outlook for their future. They were able to achieve solid revenue growth and continue investing in their products and research. With their dedication to innovation, they are sure to provide more treatments that will benefit patients around the world. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Theravance Biopharma. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Theravance Biopharma. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Theravance Biopharma. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Theravance Biopharma are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we analyzed THERAVANCE BIOPHARMA‘s financials to identify its strengths and weaknesses. According to our star chart, THERAVANCE BIOPHARMA is strong in asset, and weak in dividend, growth, profitability. We classified THERAVANCE BIOPHARMA as an ‘elephant’ company, one that is rich in assets after deducting off liabilities. This type of company may be attractive to investors who are looking for a steady return without much risk. THERAVANCE BIOPHARMA has an intermediate health score of 4/10 with regard to its cashflows and debt, which indicates that it is likely to pay off debt and fund future operations. More…
Risk Rating Analysis
Star Chart Analysis
The Company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas. Its programs include VIBATIV (telavancin), ANORO Ellipta, REYVOW, TD-1473 and others. The company’s competitors include Cerevel Therapeutics Holdings Inc, Viracta Therapeutics Inc, Island Pharmaceuticals Ltd.
– Cerevel Therapeutics Holdings Inc ($NASDAQ:CERE)
Cerevel Therapeutics Holdings Inc is a biopharmaceutical company that focuses on the treatment of neurological and psychiatric disorders. The company has a market cap of 4.26B as of 2022 and a return on equity of -36.45%. Cerevel Therapeutics Holdings Inc’s products include treatments for disorders such as Alzheimer’s disease, Parkinson’s disease, and schizophrenia. The company’s products are approved by the US Food and Drug Administration and are marketed in the United States and Europe.
– Viracta Therapeutics Inc ($NASDAQ:VIRX)
Viracta Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for virally-associated cancers. The company’s lead product candidate is VAL-083, which is being evaluated in a Phase III clinical trial in glioblastoma. Viracta also has a pipeline of other product candidates in various stages of development. The company’s market cap is $149.48M as of 2022 and its ROE is -57.78%.
– Island Pharmaceuticals Ltd ($ASX:ILA)
Island Pharmaceuticals Ltd is a pharmaceutical company with a market cap of 12.6M as of 2022. The company has a Return on Equity of 2.61%. Island Pharmaceuticals Ltd is a pharmaceutical company that manufactures and sells pharmaceutical products. The company’s products include prescription and over-the-counter drugs, vitamins, and herbal supplements.
THERAVANCE BIOPHARMA reported their financial results for FY2023 Q2, showing a 24.4% increase in total revenue from the same period in the previous year. Despite this, they reported a net income of -15.6 million, 8.2 million lower than the same period last year. Investors should therefore take into consideration these results when making decisions to invest in THERAVANCE BIOPHARMA. The company may benefit from an increase in sales and profits with better performance in the following quarters.
However, the potential risks involved in such investments should be considered.